Literature DB >> 11160262

Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells.

C Nohara1, H Akiba, A Nakajima, A Inoue, C S Koh, H Ohshima, H Yagita, Y Mizuno, K Okumura.   

Abstract

OX40 (CD134) and its ligand (OX40L) have been implicated in T cell activation and migration. In this study, we examined the contribution of these molecules to the pathogenesis of experimental autoimmune encephalomyelitis (EAE) by administering a neutralizing mAb against murine OX40L (RM134L) to proteolipid protein (139-151) peptide-induced EAE in SJL mice. Administration of RM134L effectively ameliorated the disease in both actively induced and adoptively transferred EAE models. Histological examination showed that the RM134L treatment greatly reduced mononuclear cell infiltration into the spinal cord. The RM134L treatment did not inhibit the development of pathogenic T cells, given that proliferative response and IFN-gamma production by draining lymph node cells were not reduced or rather enhanced upon restimulation with proteolipid protein (139-151) in vitro, and these cells effectively transferred EAE to naive SJL mice. Flow cytometric analyses showed that the RM134L treatment inhibited the accumulation of OX40-expressing CD4(+) T cells and the migration of adoptively transferred CD4(+) T cells in the spinal cord. Immunohistochemical staining showed that OX40L was most prominently expressed on endothelial cells in the inflamed spinal cord. These results suggest that the OX40/OX40L interaction plays a critical role for the migration of pathogenic T cells into the CNS in the pathogenesis of EAE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160262     DOI: 10.4049/jimmunol.166.3.2108

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.

Authors:  Blythe C Dillingham; Susan M Knoblach; Gina M Many; Brennan T Harmon; Amanda M Mullen; Christopher R Heier; Luca Bello; John M McCall; Eric P Hoffman; Edward M Connor; Kanneboyina Nagaraju; Erica K M Reeves; Jesse M Damsker
Journal:  Cell Mol Neurobiol       Date:  2014-11-13       Impact factor: 5.046

2.  Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.

Authors:  Zhao Xiaoyan; R Pirskanen; V Malmstrom; A K Lefvert
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 3.  Science gone translational: the OX40 agonist story.

Authors:  Andrew D Weinberg; Nicholas P Morris; Magdalena Kovacsovics-Bankowski; Walter J Urba; Brendan D Curti
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

4.  A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis.

Authors:  Srikanth Yellayi; Brendan Hilliard; Mustafa Ghazanfar; Akivaga Tsingalia; Michael H Nantz; Laura Bollinger; Fabian de Kok-Mercado; James G Hecker
Journal:  Mol Pharm       Date:  2011-07-19       Impact factor: 4.939

5.  Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice.

Authors:  Christine S Haddad; Palash Bhattacharya; Khaled Alharshawi; Alejandra Marinelarena; Prabhakaran Kumar; Osama El-Sayed; Hatem A Elshabrawy; Alan L Epstein; Bellur S Prabhakar
Journal:  Autoimmunity       Date:  2016-05-31       Impact factor: 2.815

Review 6.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

7.  Association of TNFSF4 Polymorphisms with Neuromyelitis Optica Spectrum Disorders in a Chinese Population.

Authors:  Zhiyun Lian; Ju Liu; Ziyan Shi; Hongxi Chen; Qin Zhang; Huiru Feng; Qin Du; Xiaohui Miao; Hongyu Zhou
Journal:  J Mol Neurosci       Date:  2017-10-14       Impact factor: 3.444

Review 8.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 9.  Novel antibodies targeting immune regulatory checkpoints for cancer therapy.

Authors:  Chern Siang Lee; Mark Cragg; Martin Glennie; Peter Johnson
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

10.  Activation and Costimulation of Intestinal T Cells: Independent and Collaborative Involvement of CD43, OX40, and Ly-6C.

Authors:  Dina Montufar-Solis; John R Klein
Journal:  Curr Immunol Rev       Date:  2005-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.